

Amendments to the Claims:

Please rewrite the claims as follows:

1. (Original) Use of modulators of the signal transduction pathway via the protein kinase Fyn for the prophylaxis and/or treatment of tumour diseases.
2. (Original) Use of modulators according to claim 1 in the treatment of neuroblastomas.
3. (Currently Amended) Use according to claim 1-~~or 2~~, the modulators being inhibitors of enzymes that are directly or indirectly inhibited by active Fyn.
4. (Currently Amended) Use of modulators according to claim 1-~~or 2~~ which result in an increase in Fyn activity in the tumour cells.
5. (Currently Amended) Use of modulators according to claim 1-~~or 2~~, the modulators being inhibitors of the protein kinase CSK.
6. (Currently Amended) Use of modulators according to ~~one of claims 1 to 4~~ claim 1, the modulators being inhibitors of Rho-kinase.
7. (Currently Amended) Use of modulators according to ~~one of claims 1 to 4~~ claim 1, the modulators being inhibitors of MAP-phosphatase.
8. (Currently Amended) Use of modulators according to ~~one of claims 1 to 4~~ claim 1, the modulators being activators of protein kinase C.
9. (Currently Amended) Use of modulators according to claim 1-~~or 2~~ which inhibit the proteolytic degradation of Fyn-kinase *in vivo*.

10. (Currently Amended) Use of modulators according to claim 1 ~~or 2~~, the modulators being inhibitors of phosphatases that antagonise Fyn.
11. (Currently Amended) Use of modulators according to claim 1 ~~or 2~~ which contribute to an increase in signal transduction by Fyn.
12. (Original) Use of modulators of the signal transduction pathway via the protein kinase Fyn in the production of a medicament for the suppression of the formation of metastases of tumours in the early stage.
13. (Original) Use of modulators according to claim 9, the tumour being a paediatric or adult tumour.
14. (Currently Amended) Use of modulators according to ~~one of the preceding claims~~ claim 1 as a constituent of a pharmaceutical composition, ~~characterised in that~~ wherein the composition, in addition to comprising the modulator as active ingredient, optionally comprises carrier substances and/or adjuvants.
15. (Currently Amended) Use of modulators according to ~~one of the preceding claims~~ claim 1, ~~characterised in that~~ wherein the modulator is present in the form of a pharmacologically acceptable salt, solvate, hydrate or a pharmacologically acceptable formulation.
16. (Currently Amended) Use of modulators according to ~~one of the preceding claims~~ claim 1, ~~characterised in that~~ wherein the modulator is present in the form of a prodrug comprising the modulator and at least one pharmacologically acceptable protecting group which is removed under physiological conditions.
17. (Currently Amended) Use of modulators according to ~~one of the preceding claims~~ claim 1, ~~characterised in that~~ wherein the modulator is administered orally, parenterally, rectally, by inhalation, transdermally or intranasally.